{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:17:33Z","timestamp":1783387053296,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of locoregional therapy with intraperitoneal (IP) drug delivery plus systemic chemotherapy for peritoneal carcinomatosis is understudied. We investigated progression-free survival (PFS) and overall survival (OS) in patients with peritoneal carcinomatosis from gastric, appendiceal, or small bowel adenocarcinoma who received intravenous (IV) and IP paclitaxel plus capecitabine or nilotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two separate single-institution phase II clinical trials evaluating IP and IV paclitaxel therapy plus capecitabine or nilotinib for peritoneal carcinomatosis were analyzed. Enrolled patients with peritoneal-only metastatic gastric cancer received IP and IV paclitaxel plus capecitabine. Participants with peritoneal carcinomatosis from appendiceal, gastric, or small bowel adenocarcinoma received IP and IV paclitaxel plus nilotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve patients with a median age of 46 years (range 38\u201364) received bidirectional paclitaxel plus capecitabine. Median overall PFS and OS was 5.3 months (95% confidence interval [CI] 1.5\u201313.3) and 12.5 months (95% CI 4.7\u201314.7), respectively. Seven patients with peritoneal carcinomatosis from appendiceal, gastric, or small bowel adenocarcinoma with a median age 59 years (range 46\u201369) received bidirectional paclitaxel plus nilotinib. Median PFS and OS was 3.6 months (range 2.6\u20136.6) and 8.3 months (range 2.8\u201310.2), respectively, for those receiving bidirectional paclitaxel plus nilotinib. Adverse events (AEs) were common; grade 3\u20135 AEs occurred in 90.1% (10\/11) of participants receiving IP\/IV paclitaxel plus capecitabine and 100% (7\/7) of patients receiving IP\/IV paclitaxel plus nilotinib. There was no extra-peritoneal disease progression, suggesting tumor confinement among all participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bidirectional paclitaxel-based chemotherapy plus capecitabine may delay progression of gastric adenocarcinoma with peritoneal-only metastasis. Bidirectional paclitaxel-based chemotherapy plus nilotinib was associated with mostly stable peritoneal disease in this small, heterogenous cohort. Bidirectional paclitaxel combinations are feasible and may have a role in therapy for disease stabilization in individuals with peritoneal carcinomatosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18967-2","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:51:53Z","timestamp":1768585913000},"page":"4679-4689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials"],"prefix":"10.1245","volume":"33","author":[{"given":"Amber F.","family":"Gallanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi R.","family":"Perati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Canady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra A.","family":"Satterwhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Mallory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Figueiroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibran","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy R.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Alewine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"18967_CR1","doi-asserted-by":"publisher","unstructured":"Sirody J, Kaji AH, Hari DM, Chen KT. Patterns of gastric cancer metastasis in the United States. Am J Surg. 2022;224(1 Pt B):445\u2013448. https:\/\/doi.org\/10.1016\/j.amjsurg.2022.01.024","DOI":"10.1016\/j.amjsurg.2022.01.024"},{"issue":"4","key":"18967_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","volume":"24","author":"WJ Koemans","year":"2021","unstructured":"Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800\u20139. https:\/\/doi.org\/10.1007\/s10120-021-01160-1.","journal-title":"Gastric Cancer"},{"issue":"6","key":"18967_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ijc.34780","volume":"154","author":"A Rijken","year":"2024","unstructured":"Rijken A, Pape M, Simkens GA, et al. Peritoneal metastases from gastric cancer in a nationwide cohort: incidence, treatment and survival. Int J Cancer. 2024;154(6):992\u20131002. https:\/\/doi.org\/10.1002\/ijc.34780.","journal-title":"Int J Cancer"},{"issue":"2","key":"18967_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1369\/0022155417742897","volume":"66","author":"JOAM van Baal","year":"2018","unstructured":"van Baal JOAM, van Noorden CJF, Nieuwland R, et al. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem. 2018;66(2):67\u201383. https:\/\/doi.org\/10.1369\/0022155417742897.","journal-title":"J Histochem Cytochem"},{"issue":"11","key":"18967_CR5","first-page":"937","volume":"93","author":"CA Doubeni","year":"2016","unstructured":"Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93(11):937\u201344.","journal-title":"Am Fam Physician"},{"issue":"9","key":"18967_CR6","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332. https:\/\/doi.org\/10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"18967_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"18967_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3978\/j.issn.2078-6891.2015.101","volume":"7","author":"KA Cummins","year":"2016","unstructured":"Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J Gastrointest Oncol. 2016;7(1):3\u20139. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.101.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"18967_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1245\/s10434-014-4147-y","volume":"22","author":"KI Votanopoulos","year":"2015","unstructured":"Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22(4):1274\u20139. https:\/\/doi.org\/10.1245\/s10434-014-4147-y.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"18967_CR10","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2022;29(4):2617\u201325. https:\/\/doi.org\/10.1245\/s10434-021-11087-7.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"18967_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143.","journal-title":"JAMA Surg"},{"key":"18967_CR12","doi-asserted-by":"publisher","unstructured":"Langellotti L, Fiorillo C, D\u2019Annibale G, et al. Efficacy of cytoreductive surgery (CRS) + HIPEC in gastric cancer with peritoneal metastasis: systematic review and meta-analysis. Cancers. 2024;16(10). https:\/\/doi.org\/10.3390\/cancers16101929","DOI":"10.3390\/cancers16101929"},{"key":"18967_CR13","doi-asserted-by":"publisher","unstructured":"Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911\u2013919. https:\/\/doi.org\/10.1016\/j.ejso.2015.03.231","DOI":"10.1016\/j.ejso.2015.03.231"},{"issue":"9","key":"18967_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.6004\/jnccn.2023.7055","volume":"21","author":"JA Steadman","year":"2023","unstructured":"Steadman JA, Grotz TE. Principles of surgical management of peritoneal mesothelioma. J Natl Compr Canc Netw. 2023;21(9):981\u20136. https:\/\/doi.org\/10.6004\/jnccn.2023.7055.","journal-title":"J Natl Compr Canc Netw"},{"key":"18967_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2023.02.003","volume":"171","author":"AM Praiss","year":"2023","unstructured":"Praiss AM, Zhou Q, Iasonos A, et al. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: an analysis of a randomized phase II trial. Gynecol Oncol. 2023;171:23\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.003.","journal-title":"Gynecol Oncol"},{"issue":"23","key":"18967_CR16","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688.","journal-title":"J Clin Oncol."},{"issue":"130","key":"18967_CR17","first-page":"373","volume":"61","author":"Y Liu","year":"2014","unstructured":"Liu Y, Yang T, Huang CQ, Li G, Li Y. Intraperitoneal chemotherapy for peritoneal carcinomatosis improves efficacy with acceptable safety: results of 200 cycles for 41 patients. Hepatogastroenterology. 2014;61(130):373\u20138.","journal-title":"Hepatogastroenterology"},{"issue":"Suppl 1","key":"18967_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","volume":"20","author":"D Kobayashi","year":"2017","unstructured":"Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer. 2017;20(Suppl 1):111\u201321. https:\/\/doi.org\/10.1007\/s10120-016-0662-9.","journal-title":"Gastric Cancer"},{"issue":"6","key":"18967_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/jog.15224","volume":"48","author":"PH Sugarbaker","year":"2022","unstructured":"Sugarbaker PH. Optimizing regional chemotherapy for epithelial ovarian cancer. J Obstet Gynaecol Res. 2022;48(6):1306\u201317. https:\/\/doi.org\/10.1111\/jog.15224.","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"18967_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4251\/wjgo.v7.i11.285","volume":"7","author":"H Yamaguchi","year":"2015","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: intraperitoneal chemotherapy with taxanes. World J Gastrointest Oncol. 2015;7(11):285\u201391. https:\/\/doi.org\/10.4251\/wjgo.v7.i11.285.","journal-title":"World J Gastrointest Oncol"},{"key":"18967_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae116","author":"NAD Guchelaar","year":"2024","unstructured":"Guchelaar NAD, Nasserinejad K, Mostert B, et al. Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis. Br J Surg. 2024. https:\/\/doi.org\/10.1093\/bjs\/znae116.","journal-title":"Br J Surg"},{"issue":"31","key":"18967_CR22","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.06.8429.","journal-title":"J Clin Oncol."},{"issue":"11","key":"18967_CR23","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-24-3049","volume":"31","author":"SJ Shin","year":"2025","unstructured":"Shin SJ, O\u2019Sullivan Coyne G, Kummar S, et al. A phase I study of nilotinib in combination with paclitaxel in patients with advanced solid tumors. Clin Cancer Res. 2025;31(11):2124\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3049.","journal-title":"Clin Cancer Res"},{"key":"18967_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"key":"18967_CR25","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017. Accessed September 20, 2025. ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"18967_CR26","doi-asserted-by":"publisher","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132-137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","DOI":"10.1016\/j.ejca.2016.03.081"},{"issue":"3","key":"18967_CR27","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","volume":"30","author":"BL Green","year":"2023","unstructured":"Green BL, Blumenthaler AN, Gamble LA, et al. Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials. Ann Surg Oncol. 2023;30(3):1852\u201360. https:\/\/doi.org\/10.1245\/s10434-022-12761-0.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"18967_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III Gastripec-I trial. J Clin Oncol. 2024;42(2):146\u201356. https:\/\/doi.org\/10.1200\/JCO.22.02867.","journal-title":"J Clin Oncol"},{"issue":"1","key":"18967_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"issue":"19","key":"18967_CR30","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139. https:\/\/doi.org\/10.1200\/JCO.2018.77.8613.","journal-title":"J Clin Oncol"},{"issue":"6","key":"18967_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","volume":"32","author":"Y Yonemura","year":"2006","unstructured":"Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661\u20135. https:\/\/doi.org\/10.1016\/j.ejso.2006.03.007.","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"18967_CR32","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00384-020-03649-0","volume":"35","author":"K Murono","year":"2020","unstructured":"Murono K, Nozawa H, Nagata H, et al. Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases. Int J Colorectal Dis. 2020;35(10):1945\u20139. https:\/\/doi.org\/10.1007\/s00384-020-03649-0.","journal-title":"Int J Colorectal Dis"},{"key":"18967_CR33","doi-asserted-by":"publisher","unstructured":"Yan C, Yang Z, Shi Z, et al. Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial. J Clin Oncol. 2025;43(4_suppl):327-327. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.327","DOI":"10.1200\/JCO.2025.43.4_suppl.327"},{"issue":"Suppl 1","key":"18967_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13193-023-01715-x","volume":"14","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee A, Kazi M, Ostwal V, Ramaswamy A, Desouza A, Saklani A. Bidirectional chemotherapy in advanced colorectal cancer peritoneal metastases. Indian J Surg Oncol. 2023;14(Suppl 1):192\u20137. https:\/\/doi.org\/10.1007\/s13193-023-01715-x.","journal-title":"Indian J Surg Oncol"},{"issue":"13","key":"18967_CR35","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1158\/0008-5472.CAN-17-0489","volume":"77","author":"SL Holbeck","year":"2017","unstructured":"Holbeck SL, Camalier R, Crowell JA, et al. The national cancer institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic Activity. Cancer Res. 2017;77(13):3564\u201376. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0489.","journal-title":"Cancer Res"},{"issue":"2","key":"18967_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/0008-5472.CAN-18-3539","volume":"80","author":"T Navas","year":"2020","unstructured":"Navas T, Kinders RJ, Lawrence SM, et al. Clinical evolution of epithelial-mesenchymal transition in human carcinomas. Cancer Res. 2020;80(2):304\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3539.","journal-title":"Cancer Res"},{"issue":"1","key":"18967_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12885-023-10680-1","volume":"23","author":"M Senthil","year":"2023","unstructured":"Senthil M, Dayyani F. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis\u2014STOPGAP trial. BMC Cancer. 2023;23(1):209. https:\/\/doi.org\/10.1186\/s12885-023-10680-1.","journal-title":"BMC Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18967-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18967-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18967-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:27:29Z","timestamp":1776256049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18967-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["18967"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18967-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christine Alewine has received drug-only support for clinical trials from AstraZeneca, Minneamrita, and ProDa LLC and research funds provided to her institution from HCW Biologics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}